Literature DB >> 33834416

Psychedelic Medicines in Major Depression: Progress and Future Challenges.

Jose Carlos Bouso1, Genís Ona2, Rafael G Dos Santos2,3,4, Jaime E C Hallak2,3.   

Abstract

The volume of research on the therapeutic use of psychedelic drugs has been increasing during the last decades. Partly because of the need of innovative treatments in psychiatry, several studies have assessed the safety and efficacy of drugs like psilocybin or ayahuasca for a wide range of mental disorders, including major depression. The first section of this chapter will offer an introduction to psychedelic research, including a brief historical overview and discussions about appropriate terminology. In the second section, the recently published clinical trials in which psychedelic drugs were administered to patients will be analysed in detail. Then, in the third section, the main neurobiological mechanisms of these drugs will be described, noting that while some of these mechanisms could be potentially associated with their therapeutic properties, they are commonly used as adjuvants in psychotherapeutic processes. The last section suggests future challenges for this groundbreaking field of research and therapy.

Entities:  

Keywords:  Ayahuasca; Depression; Hallucinogens; Mental health; Psilocybin; Psychedelics

Mesh:

Substances:

Year:  2021        PMID: 33834416     DOI: 10.1007/978-981-33-6044-0_26

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  73 in total

1.  Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.

Authors:  Rafael Faria Sanches; Flávia de Lima Osório; Rafael G Dos Santos; Ligia R H Macedo; João Paulo Maia-de-Oliveira; Lauro Wichert-Ana; Draulio Barros de Araujo; Jordi Riba; José Alexandre S Crippa; Jaime E C Hallak
Journal:  J Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.153

Review 2.  Psychiatry & the psychedelic drugs. Past, present & future.

Authors:  James J H Rucker; Jonathan Iliff; David J Nutt
Journal:  Neuropharmacology       Date:  2017-12-25       Impact factor: 5.250

3.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

Authors:  Charles S Grob; Alicia L Danforth; Gurpreet S Chopra; Marycie Hagerty; Charles R McKay; Adam L Halberstadt; George R Greer
Journal:  Arch Gen Psychiatry       Date:  2010-09-06

4.  Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report.

Authors:  Flávia de L Osório; Rafael F Sanches; Ligia R Macedo; Rafael G dos Santos; João P Maia-de-Oliveira; Lauro Wichert-Ana; Draulio B de Araujo; Jordi Riba; José A Crippa; Jaime E Hallak
Journal:  Braz J Psychiatry       Date:  2015 Jan-Mar       Impact factor: 2.697

5.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

6.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

7.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Authors:  R L Carhart-Harris; M Bolstridge; C M J Day; J Rucker; R Watts; D E Erritzoe; M Kaelen; B Giribaldi; M Bloomfield; S Pilling; J A Rickard; B Forbes; A Feilding; D Taylor; H V Curran; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2017-11-08       Impact factor: 4.530

8.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083

9.  Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.

Authors:  Peter Gasser; Dominique Holstein; Yvonne Michel; Rick Doblin; Berra Yazar-Klosinski; Torsten Passie; Rudolf Brenneisen
Journal:  J Nerv Ment Dis       Date:  2014-07       Impact factor: 2.254

10.  Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.

Authors:  Fernanda Palhano-Fontes; Dayanna Barreto; Heloisa Onias; Katia C Andrade; Morgana M Novaes; Jessica A Pessoa; Sergio A Mota-Rolim; Flávia L Osório; Rafael Sanches; Rafael G Dos Santos; Luís Fernando Tófoli; Gabriela de Oliveira Silveira; Mauricio Yonamine; Jordi Riba; Francisco R Santos; Antonio A Silva-Junior; João C Alchieri; Nicole L Galvão-Coelho; Bruno Lobão-Soares; Jaime E C Hallak; Emerson Arcoverde; João P Maia-de-Oliveira; Dráulio B Araújo
Journal:  Psychol Med       Date:  2018-06-15       Impact factor: 7.723

View more
  2 in total

1.  How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Authors:  Manon van den Berg; Igor Magaraggia; Rudy Schreiber; Todd M Hillhouse; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2022-03-29       Impact factor: 4.415

2.  Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.

Authors:  Dóra Révész; Genís Ona; Giordano N Rossi; Juliana M Rocha; Rafael G Dos Santos; Jaime E C Hallak; Miguel Á Alcázar-Córcoles; José C Bouso
Journal:  Front Psychiatry       Date:  2021-06-16       Impact factor: 5.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.